FiercePharma

@FiercePharma

FiercePharma's 140, written by Tracy Staton. Join 90,000 pharma insiders on our free newsletter at .

West End, District of Columbia
Vrijeme pridruživanja: prosinac 2008.

Tweetovi

Blokirali ste korisnika/cu @FiercePharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FiercePharma

  1. prije 9 sati

    Novo extends China employees' holiday amid coronavirus threat; expects manufacturing to start up next week

    Poništi
  2. prije 11 sati
    Poništi
  3. prije 12 sati

    GlaxoSmithKline's spinoff plan is here—and it may not be limited to consumer health

    Poništi
  4. prije 12 sati

    Federal prosecutors snare 3rd generics exec in price-fixing investigation

    Poništi
  5. prije 13 sati

    Gilead CEO O'Day feels 'sense of urgency' on dealmaking as Kite writedowns add up

    Poništi
  6. prije 13 sati

    Novo's next-gen GLP-1 Ozempic smashes blockbuster barrier amid ramp-up for Rybelsus rollout

    Poništi
  7. prije 13 sati

    Merck preaches the value of ‘focus’ as it spins off $6.5B women’s health, biosimilars units

    Poništi
  8. 30. sij
    Poništi
  9. 30. sij

    Ocrevus, Hemlibra offset Roche's biosim loss. But what about those lackluster Xofluza sales?

    Poništi
  10. 30. sij

    Alexion to its detractors: Take a look at our Soliris switching and budding pipeline

    Poništi
  11. 30. sij

    Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin

    Poništi
  12. 30. sij
    Poništi
  13. 30. sij

    Biogen’s Tecfidera holds its own in MS as competitive and generic threats loom

    Poništi
  14. 30. sij
    Poništi
  15. 30. sij
    Poništi
  16. 29. sij

    Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?

    Poništi
  17. 29. sij
    Poništi
  18. 29. sij
    Poništi
  19. 29. sij

    Incyte doubles down on atopic dermatitis push with trial win for ruxolitinib cream

    Poništi
  20. 29. sij
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·